How long is long enough to secure disease control after low-dose-rate brachytherapy in combination with other modalities in intermediate-risk, localized prostate cancer?
Fumihiko Urabe(Jikei University School of Medicine), Shin Egawa, Keiji Yasue(Higashi Nagoya National Hospital), Manabu Aoki(Jikei University School of Medicine), Shun Sato(Jikei University School of Medicine), Hiroshi Sasaki(Jikei University School of Medicine), Kenta Miki(Jikei University School of Medicine), Takahiro Kimura(Jikei University School of Medicine), Hiroyuki Takahashi(Jikei University School of Medicine), Kojiro Tashiro(Jikei University School of Medicine), Kosuke Iwatani(Jikei University School of Medicine)
Cited by 10
Related Papers
Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study
|The Lancet Oncology|2020|631
Extracellular vesicles as biomarkers and therapeutic targets for cancer
|American Journal of Physiology-Cell Physiology|2019|412
Circulating miRNA panels for specific and early detection in bladder cancer
|Cancer Science|2018|282
Autophagy modulates osteoarthritis‐related gene expression in human chondrocytes
|Arthritis & Rheumatism|2011|265
Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer
|Clinical Cancer Research|2019|129